Actively Recruiting
Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication
Led by Jamil Cedeño Mora · Updated on 2025-12-15
1200
Participants Needed
12
Research Sites
117 weeks
Total Duration
On this page
Sponsors
J
Jamil Cedeño Mora
Lead Sponsor
F
Fundación para la Investigación Biomédica del Hospital Gregorio Maranon
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock. The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin. The main research questions are: * Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock? * What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients? Participants will: * Be admitted to an ICU with a diagnosis of septic shock. * Receive vasopressin as an adjunct to norepinephrine for hemodynamic support. * Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system. * Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.
CONDITIONS
Official Title
Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Admitted to an Intensive Care Unit with a diagnosis of septic shock
- Age 18 years or older at ICU admission
- Receiving vasopressin in addition to norepinephrine
- Septic shock defined by sustained low blood pressure or serum lactate above 2 mmol/L
- Adequate but unsuccessful fluid resuscitation
- Use of vasopressors to maintain mean arterial pressure above 65 mmHg
- Probable or confirmed infection causing the septic shock
You will not qualify if you...
- Pregnancy
- Ischemic cardiogenic shock
- Acute intestinal ischemia
- Readmission to the Intensive Care Unit
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Consorci Sanitari de Terrassa
Terrassa, BARCELONA, Spain, 08227
Actively Recruiting
2
Hospital Universitario de Getafe
Getafe, Madrid, Spain, 28905
Actively Recruiting
3
Hospital Universitario La Princesa
Madrid, Madrid, Spain, 28006
Actively Recruiting
4
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain, 28007
Actively Recruiting
5
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain, 28034
Actively Recruiting
6
Hospital Universitario Clínico San Carlos
Madrid, Madrid, Spain, 28040
Actively Recruiting
7
Hospital Universitario Doce de Octubre
Madrid, Madrid, Spain, 28041
Actively Recruiting
8
Hospital Universitario La Paz
Madrid, Madrid, Spain, 28046
Actively Recruiting
9
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain, 28222
Actively Recruiting
10
Hospital Universitario Rey Juan Carlos
Móstoles, Madrid, Spain, 28933
Actively Recruiting
11
Hospital Universitario y Politécnico de La Fe
Valencia, Valencia, Spain, 46026
Actively Recruiting
12
Hospital Universitario Miguel Servet
Zaragoza, ZARAGOZA, Spain, 50009
Actively Recruiting
Research Team
J
Jamil Antonio Cedeño Mora
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here